BioSyent Current Cash

The latest current cash for RX.V is $5.2M as of June 2026. That compares with $14M in the prior-year period — down 62.8% year over year. Investors often review this figure alongside BioSyent's historical trend and sector peers before judging valuation or financial health.

Over the past year, RX.V's current cash moved from $14M to $5.2M — a 62.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioSyent's operating scale or balance-sheet position.

A current cash figure of $5.2M for RX.V is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RX.V's current cash ($5.2M), review year-over-year change from $14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.